Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

New China Innovation Policies Having Unintended Consequences?

This article was originally published in PharmAsia News

Executive Summary

Recent media coverage of “failed” drugs being given a second life in China has raised a raft of issues, including whether preference should be given to the domestic industry, with its poor quality record and scant innovation, and if the impact of the recent official redefinition of a new drug is really spurring innovation or just driving new types of licensing deals.



Related Companies